Optimizing COPD treatment in patients with lung- or head and neck cancer does not improve quality of life – a randomized, pilot, clinical trial
Background: Chronic obstructive pulmonary disease (COPD) is a common comorbidity in patients with lung and head- and neck cancer. Patients with lung cancer who also suffer from COPD have a worse prognosis than patients with lung cancer and no COPD. It has previously been shown that diagnosis and tre...
Main Authors: | Magnus Gottlieb, Anders Mellemgaard, Kristoffer Marsaa, Nina Godtfredsen |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2020-01-01
|
Series: | European Clinical Respiratory Journal |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/20018525.2020.1731277 |
Similar Items
-
2017 Global Initiative for Chronic Obstructive Lung Disease reclassifies half of COPD subjects to lower risk group
by: Högman M, et al.
Published: (2018-01-01) -
Biomarkers for Comorbidities Modulate the Activity of T-Cells in COPD
by: Kaschin Jamal Jameel, et al.
Published: (2021-07-01) -
One-year mortality after severe COPD exacerbation in Bulgaria
by: Evgeni Mekov, et al.
Published: (2016-12-01) -
Soluble urokinase plasminogen activator receptor predicts mortality in exacerbated COPD
by: Nina S. Godtfredsen, et al.
Published: (2018-05-01) -
Prevalence of concealed and overt chronic renal failure in patients with COPD
by: Abdelsadek H. Al-Aarag, et al.
Published: (2017-01-01)